NCT00870714Unknown不适用
Neoadjuvant Therapy With Docetaxel and Ketoconazole in Patients With High-Risk Prostate Cancer: A Pilot Study
Kansas City Veteran Affairs Medical Center1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2004年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- To determine the pathologic response rate of neoadjuvant therapy with the combination of docetaxel and ketoconazole given to patients who are at a high risk of recurrence of prostate cancer.
研究概览
简要总结
Eligible patients with high-risk prostate cancer who are scheduled to undergo radical prostatectomy will receive four cycles of therapy with ketoconazole and docetaxel prior to surgery resection. A cycle of therapy is defined as 21 days (three weeks). Pharmacokinetic analysis will be performed with the first and second cycle of therapy. All patients will be evaluated for toxicity, tumor response, and recurrence.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically proven adenocarcinoma of the prostate.
- •Patients must meet at least one of the following high risk criteria:
- •PSA > 20
- •Gleason score 8 or greater
- •Presence of pathological Gleason grade 4 or higher as the majority sum on biopsy core
- •Greater than 50% of cores at time of biopsy positive for cancer
- •Clinical Stage T3 Disease
- •Patients must have PS of 0-1(ECOG) and medically deemed a surgical candidate for radical prostatectomy.
- •Age > or = to
- •Patients with a pre-existing peripheral neuropathy of equal to or greater than grade two are ineligible.
- •Serum Creatinine must be < or equal to 2.0mg/dl.
- •Patients must currently not receiving any drug which is metabolized by cytochrome P450-3A4 including the statins, cyclosporin, terfenadine and erythromycin.
- •Prior to receiving any dose of docetaxel, patients should have absolute neutrophil counts > 1,500, hemoglobin > 8.0 g/dl and platelet counts > 100,000/mm
- •Patients with bilirubin elevated above institutional upper limit of normal (ULN)must be excluded. Transaminases (SGOT and/or SGPT) may be up to 5.0 x institutional upper limit of normal (ULN) if alkaline phosphatase is < ULN, or alkaline phosphatase may be up to 5 x ULN if transaminases are < ULN. However, patients who have both transaminase elevation > 1.5 x ULN and alkaline phosphatase > 2.5 x ULN are not eligible for this study (due to decrease clearance of docetaxel and increased risk of toxicity).
- •Patients receiving concurrent warfarin are eligible but require monitoring of protime on a weekly basis.
- •Patients with clinical stage T4 disease are not eligible.
- •Patients must not had have received prior treatment with surgery, radiation or hormone deprivation.
- •Patients with other primary malignancies previously treated with chemotherapeutic agents are not eligible.
- •Patients must not have had a history of peptic ulcer disease requiring treatment with surgery or endoscleral.
- •Patients requiring corticosteroids for other systemic diseases are not eligible.
- •Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 are not eligible.
- •All patients must sign informed consent.
- •Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.
排除标准
- 未提供
研究组 & 干预措施
A
Experimental
Eligible patients with high-risk prostate cancer who are scheduled to undergo radical prostatectomy will receive four cycles of therapy with ketoconazole and docetaxel prior to surgery resection
干预措施: Docetaxel (Drug)
A
Experimental
Eligible patients with high-risk prostate cancer who are scheduled to undergo radical prostatectomy will receive four cycles of therapy with ketoconazole and docetaxel prior to surgery resection
干预措施: Ketoconazole (Drug)
结局指标
主要结局
To determine the pathologic response rate of neoadjuvant therapy with the combination of docetaxel and ketoconazole given to patients who are at a high risk of recurrence of prostate cancer.
时间窗: One year
次要结局
- To assess in preliminary fashion whether of this treatment will decrease the incidence of biochemical recurrence and provide a survival benefit as compared to patients with local treatment only or other adjuvant therapies.(One Year)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
eoadjuvant docetaxel prior to radical prostatectomy for high risk localised prostate cancer. Evaluation of biological and functional imaging surrogates of therapy efficacy. - CANCAP01eoadjuvant docetaxel prior to radical prostatectomy for high risk localised prostate cancer. Evaluation of biological and functional imaging surrogates of therapy efficacyEUCTR2009-014491-21-GBCambridge University Hospitals NHS Trust15
已完成
2 期
preoperative docetaxel chemotherapy and radical prostatectomy for metastatic prostate cancerMetastatic, untreated, high-riskProstate CancerJPRN-jRCT1031180387Horie Shigeo2
已完成
2 期
Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate CancerProstate CancerNCT01250717Beth Israel Deaconess Medical Center28
终止
1 期
Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's LymphomaNon-Hodgkins LymphomaProstate CancerNCT00848601Astex Pharmaceuticals, Inc.14
终止
2 期
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair DeficienciesHormone-Resistant Prostate CancerMetastatic Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate CancerNCT02985021Seattle Institute for Biomedical and Clinical Research2